Chemokines and their receptors are orchestrators of cell migration in humans. Because dysregulation of the receptor-chemokine system leads to inflammation and cancer, both chemokines and receptors are highly sought therapeutic targets. Yet one of the barriers for their therapeutic targeting is the limited understanding of the structural principles behind receptor-chemokine recognition and selectivity. The existing structures do not include CXC subfamily complexes and lack information about the receptor distal N-termini, despite the importance of the latter in signaling, regulation, and bias. Here we report the discovery of the geometry of the complex between full-length CXCR4, a prototypical CXC receptor and driver of cancer metastasis, and its endogenous ligand CXCL12. By comprehensive disulfide crosslinking, we establish the existence and the structure of a novel interface between the CXCR4 distal N-terminus and CXCL12 β1-strand, while also recapitulating earlier findings from NMR, modeling and crystallography of homologous receptors. A crosslinking-informed high-resolution model of the CXCR4-CXCL12 complex pinpoints the interaction determinants and reveals the occupancy of the receptor major subpocket by the CXCL12 proximal N-terminus.
Introduction
As orchestrators of cell migration, chemokines and their receptors are critical to many physiological and disease-related processes including embryogenesis and organ development, immune surveillance, inflammation, and cancer metastasis [1] . Chemokines are secreted 8-12 kDa proteins that share a conserved topology and are classified into four subfamilies (CC, CXC, CX 3 C, and XC) based on the number and arrangement of cysteine residues in their N-termini. Chemokine receptors are class A G protein-coupled receptors (GPCRs) that preferentially recognize chemokines from individual subfamilies. However, within their subfamily, many receptors respond to multiple chemokines, often in different or biased ways [2] ; additionally, there are examples of receptor-chemokine interactions across subfamilies, notably involving atypical and virally-encoded receptors and chemokines [3] . The complexity of the resulting interaction and signaling network has been cited as a reason for the failures of numerous chemokine receptor-targeting clinical candidates, with only two small molecule drugs (CXCR4 and CCR5 antagonists) approved by the FDA thus far [2, 4, 5] . Another reason is the limited understanding of structural principles that determine receptor-chemokine recognition and selectivity, which poses challenges for the development of anti-chemokine therapeutics with desired pharmacological profiles.
Recently, X-ray structures of several receptor complexes with CC and CX 3 C chemokines were determined, and have provided insight into general principles of chemokine binding and receptor activation [6] [7] [8] [9] . The structures revealed extensive and compositionally complex interaction interfaces with functionally distinct parts that confirm and expand the canonical "two-site" hypothesis of receptor-chemokine recognition [10] [11] [12] [13] [14] . The two classical parts of the interface are chemokine recognition site 1, CRS1, where the proximal N-terminus of the receptor binds the globular core of the chemokine, and CRS2 where the transmembrane (TM) domain binding pocket of the receptor interacts with the N-terminal signaling domain of the chemokine. The structures also revealed an unexpected intermediate anchoring site (CRS1.5) between the conserved disulfide bond of the chemokine and the conserved proline-cysteine motif in the proximal N-terminus of the receptor.
Despite these advances, our understanding of chemokine-receptor interaction remains incomplete for two reasons. First, CXC chemokine complexes have not yet yielded to structure determination efforts. Also, the distal N-termini of receptors are invariably disordered in crystal structures solved thus far. For many receptorchemokine complexes, the N-terminus is known to play an important role in affinity and selectivity [15] [16] [17] [18] , both of which may be further fine-tuned by post-translational sulfation of tyrosine residues [19, 20] . Furthermore, the distal N-terminus has been proposed to be a determinant of chemokine-mediated signaling [18, 21, 22] , and to contribute to signaling bias [23] . These studies established the functional importance of receptor N-termini; however, their interaction geometry with the chemokines remains elusive (S1 Table) , which is a critical barrier for our understanding of how chemokines control diverse signaling events. In complementary studies, the interaction geometries have been explored by nuclear magnetic resonance (NMR) with isolated Nterminal peptides of the receptors [24] [25] [26] [27] [28] [29] [30] [31] (S1 Table) . Although these efforts have captured some important residue pairings, the absence of spatial constraints from the TM domain of intact receptors has led to geometric inconsistencies across the NMR structures and in relation to the crystallographic structures of the TM domains [32, 33] .
Here, we aimed to resolve these inconsistencies and characterize the geometry of the complex of the full length CXC chemokine receptor, CXCR4, and its endogenous chemokine CXCL12, via comprehensive disulfide crosslinking (S1 Table) and crosslinking-guided molecular modeling. Building upon prior experimental and modeling efforts that focused on CRS2 [6, 33] , we refined the model and completed it by revealing the structural basis for the binding of the full receptor N-terminus to various regions of the chemokine globular core. Consistent with pharmacological evidence of the involvement of receptor distal N-terminus in chemokine recognition [18, 22] , we elucidated the geometry of its interactions with the chemokine β1-strand, and validated the so-called CRS0.5 previously proposed for a homologous receptor [34] . The complete model provides insights into the role of select polar residues in the receptor and the chemokine, and explains the effects of receptor tyrosine sulfation. Furthermore, as complexes containing CXC chemokines have not yet been crystallized, the present experimentally validated full-length CXC receptor-chemokine model is valuable for the analyses of recognition specificity across the major chemokine families.
Results

A structural hypothesis of the CXCR4-CXCL12 interaction guided by CXCL12 chemical properties
Disulfide crosslinking [6, 35] , our chosen approach to revealing the geometry of the CXCR4-CXCL12 complex, involves co-expression of pairs of receptor and chemokine Cys mutants in Sf9 insect cells, and monitoring the formation of covalent complexes (S1 Fig) . Because comprehensive all-to-all pairwise mutagenesis (estimated 54 chemokine core residues×25 receptor N-terminus residues = 1350 pairs) is impractical, we sought guidance for the placement of the CXCR4 N-terminus from the structural and chemical properties of CXCL12 itself. Peptide binding sites on globular proteins often combine a rigid and hydrophobic center with a flexible polar rim [36, 37] , or utilize β-sheet-like backbone interactions [38, 39] . Accordingly, we evaluated these properties for the exposed structural elements of the CXCL12 globular core (the N-loop, 3 10 helix, β1-strand, 30s loop, 40s loop and β3-strand, Fig 1A and 1B) . Mapping was performed using multiple crystal structures of CXCL12 and yielded the following observations (Fig 1A-I; S2 Table) :
• High degree of solvent exposure and flexibility of residues in the N-loop (12-RFFESH-17), particularly H17, suggest likely involvement in protein-protein interactions ( Fig 1A and 1D-1G ). Such exposure and dynamics are also consistent with fast radiolytic oxidation of these residues in an earlier CXCL12 footprinting experiment [34] .
• High degree of solvent exposure and flexibility also characterize the 40s loop, including the asparagine cluster 44-NNN-46 ( Fig 1A and 1D-1G ).
• The N-loop and the 40s loop together frame a groove ( Fig 1D, 1F and 1H, black stroke) on the chemokine surface whose base is lined by the rigid and almost completely buried aliphatic residues from the β3-strand;
this composition (rigid hydrophobic bottom and polar flexible rims) is common in peptide-binding interfaces [36, 37] .
• The β1-strand (25-HLKIL-29) presents a "path" of solvent-accessible residue backbones ( Fig 1I, black stroke), whereas the side chains have limited solvent accessibility due to secondary structure constraints ( Fig 1A and 1E ); this arrangement favors backbone-backbone interactions with potential binding partners.
In fact, the β1-strand of CXC chemokines mediates their homodimerization [40] and may be "repurposed" for binding to the receptor (supported by modeling [41] and the recent NMR structure with the N-terminal peptide of CXCR4 [25]) or other proteins [42] .
• The mostly buried aliphatic residues L26 and I28 in the β1-strand ( Fig 1A and 1E ) likely have a structural role in supporting the integrity of the β-sheet.
In the available CXCL12 crystal structures, the N-loop, 30s loop, and 40s loop appeared to adopt distinct conformations in a coordinated fashion ( Fig 1A and 1C ; S3 Table) . It is not known whether all or only some of the resulting principal conformations of CXCL12 are relevant for its interaction with the receptor, which may have implications for generating a high-resolution model of the complex (addressed below).
Altogether, this analysis delineated two broad patches on the chemokine surface whose properties made them favorable for interactions with the receptor N-terminus: the N-loop/40s loop groove on one side, and the β1strand on the other. Taking into account the structural constraints imposed by the previously published partial complex models [6, 43] , we put forward a low-resolution hypothesis to broadly delineate the interaction patches and help guide selection of residue groups for crosslinking. According to this hypothesis, the proximal Nterminus of CXCR4 (CRS1), binds in the chemokine's N-loop/40s loop groove ( Fig 1J and 1K , dark blue), while the rest of the N-terminus wraps around the chemokine to interact with the CXCL12 β1-strand, potentially extending the chemokine β-sheet ( Fig 1J and 1K , light green). The latter interface is consistent with our earlier model of the homologous receptor, ACKR3 [34] . Given the abundance of positive charges on CXCL12 ( Fig 1A and S2 Fig) , we also postulated that the receptor-chemokine interaction is largely driven by electrostatics. Next, we sought to validate and refine this structural hypothesis using geometric constraints from disulfide crosslinking.
Flow cytometry-based disulfide crosslinking identifies prominent CXCR4-CXCL12 residue proximities along the predicted interaction sites
First, the proposed interaction between the distal N-terminus of CXCR4 (residues 3-GISIY-7 and S9) and the β1-strand of CXCL12 (residues 25-HLKIL-29) ( Fig 1H) was systematically and comprehensively probed by disulfide crosslinking. To avoid any bias towards the initial hypothesis, we coexpressed every pair of receptor and chemokine cysteine mutants in this interface in Sf9 cells (30 pairs total), after which covalent complexes were detected on the cell surface by flow cytometry via the chemokine C-terminal HA tag (S1 Fig) . This was possible because unless it is bound covalently, CXCL12 quickly dissociates from CXCR4 [44] and becomes undetectable on the insect cell surface [35] . In all cases, the antagonist variant [P2G]CXCL12 was used [10] , because like many agonists, WT CXCL12 does not form high affinity complexes with the receptor, except in the presence of G protein [45] [46] [47] . In the crosslinking experiments, the previously crystallized disulfidecrosslinked complex of CXCR4(D187C) with the viral chemokine antagonist vMIP-II(W5C) [6] was used as a positive control, and combinations of these mutants with other chemokine and receptor mutants as negative controls (12 additional mutant pairs).
The data demonstrated positive crosslinks between [P2G]CXCL12 H25C, K27C and L29C with the distal Nterminus of the receptor, confirming their proximity and interaction (Fig 2A and 2B ). [P2G]CXCL12(L29C) strongly crosslinked with CXCR4(G3C) (107.2% efficiency compared to CXCR4(D187C)-vMIP-II(W5C)) (Fig   2A; S4 Table) . Likewise, the G3C-K27C (135.5%), G3C-H25C (81.7%), Y7C-H25C (88.0%), and S9C-H25C (81.2%) receptor-chemokine combinations crosslinked comparably to CXCR4(D187C)-vMIP-II(W5C), while I4C-H25C, S5C-K27C, S5C-H25C crosslinked moderately well (>50% efficiency) (Fig 2A; S4 Table) .
Although the crosslinking pattern did not reveal a one-to-one correspondence between the receptor and chemokine residues at this interaction interface, definitive asymmetry was observed: CXCR4 S5C crosslinked with [P2G]CXCL12 K27C and H25C, but not L29C (Fig 2A and 2B) , while the only mutant to crosslink with L29C was CXCR4 G3C (Fig 2A and 2B) . The observed crosslinking pattern supports an anti-parallel geometry, in contrast to a parallel one, for the potential β-sheet between the CXCR4 N-terminus and CXCL12 β1-strand ( Fig 1K and 2B) .
Interestingly, all interactions involving [P2G]CXCL12 L26C and I28C mutants were strongly disfavored ( Fig   2A) . In control experiments with ACKR3 that not only binds [P2G]CXCL12, but also displays it on the Sf9 cell surface without crosslinking due to slow off-rates [18, 35] , negligible surface chemokine was detected for [P2G]CXCL12 L26C and I28C (S3 Fig) . This suggests that these mutant chemokines were misfolded, in agreement with the proposed structural role of L26 and I28 (Fig 1) .
Next, we systematically probed the crosslinking propensities between CXCR4 proximal N-terminus residues (16-MGVGDYDSMK-25) and parts of the [P2G]CXCL12 N-loop and 3 10 helix (15-ESHVARAN-22) ( Fig 1J) .
Residue R20 was omitted from mutagenesis, because it is oriented in the opposite direction from the N-loop/40s loop groove in all CXCL12 structures, and thus is unlikely to interact with the CXCR4 proximal N-terminus.
We also generated CXCL12 40s loop mutants K43C and N44C and included the positive and negative controls as above. Again, to avoid bias, each-to-each receptor-chemokine residue pair crosslinking was attempted within this broadly defined patch, resulting in a total of 100 pairs. This crosslinking effort captured CXCR4 K25C crosslinking with [P2G]CXCL12 E15C and S16C, recapitulating previous observations with WT CXCL12 [33] .
In fact, these residue pairs crosslinked with greater efficiency than the CXCR4(D187C)-vMIP-II(W5C) control ( Fig 2C and 2D ; S4 Table) . Residues Y21, S23 and M24 also crosslinked with [P2G]CXCL12 E15 and S16.
Despite the crosslinking promiscuity of CXCR4 S18, it was the only residue to strongly crosslink with N22 and to moderately crosslink with N44 in the 40s loop. Furthermore, there was considerable (although less efficient) crosslinking between CXCR4 residues M16-S18 and [P2G]CXCL12 A21. These results provide strong evidence for the interaction between the proximal N-terminus of CXCR4 and the N-loop/40s loop groove of CXCL12 ( Fig 1J, 2C and 2D).
To build confidence in the specificity of the flow cytometry findings and complete the crosslinking set, we coexpressed receptor and chemokine mutants across the predicted interaction sites, that is, CXCR4 CRS1 mutants with proposed [P2G]CXCL12 CRS0.5 mutants and vice versa. As expected, weak or negligible crosslinking was observed between the proximal N-terminus of CXCR4 (CRS1) and the CXCL12 β1-strand ( Fig 2E) .
Similar to crosslinking in the proposed CRS0.5 interface (Fig 2A and 2Ba ), H25 demonstrated a pattern of multiple weak crosslinks, suggesting lack of specificity for this residue. An additional moderate crosslink was detected between CXCR4 G19C and [P2G]CXCL12 K27C, which was hard to reconcile in our hypothesized model; therefore, this pair was included in follow-up pull-down/Western blotting studies (below).
Unexpectedly, when probing the opposite combination, we observed considerable crosslinking between the distal N-terminus of CXCR4 (CRS0.5) and [P2G]CXCL12 H17C ( Fig 2F) . Similar to H25C, the lack of specificity for CXCL12 H17C may in part be explained by its unusually high solvent accessibility in the CXCL12 structures ( Fig 1A and 1D ; S2 Table) . This proximity contradicts our initial structural hypothesis and suggests a potential alternative or a transient intermediate conformation where the distal N-terminus of CXCR4 binds to the N-loop/40s loop groove of CXCL12; this conformation is likely facilitated by the similarity of the physico-chemical properties in the distal and proximal N-terminal sequences of CXCR4 (2-EGISIYTS-9 vs 15-EMGSGDYDS-23). The strongest cross-interface pair of CXCR4(S9C) with CXCL12(H17C) was also included in the follow-up pull-down experiments (below).
Low throughput follow-up characterization of complexes by pull-down and Western blotting corroborates proximities identified by flow cytometry
Based on the flow cytometry data, a small number of receptor-chemokine combinations were selected for verification using an orthogonal and established method [6, 34, 35] . The crosslinked complexes were extracted from detergent-solubilized Sf9 membranes via metal affinity pull-down using a His-tag on the receptor; the pulled down complexes were separated on a non-reducing SDS-PAGE and probed for co-migrating chemokine by Western blotting (S1 Fig) . These experiments included several pairs that appeared strongly crosslinked in the flow cytometry experiments (Fig 2) , as well as select weakly crosslinked (Y21C-N22C and Y21C-N44C, Fig   2C) or non-crosslinked (K25C-A21C) combinations.
Consistent with expectations, the control pair of CXCR4(D187C) and vMIP-II(W5C) provided one of the brightest bands on anti-HA blots, indicating a large amount of HA-tagged chemokine co-migrating, and hence crosslinked, with the receptor ( Fig 3A) . Comparable amounts of co-migrating chemokine were observed when CXCR4(K25C) was co-expressed with [P2G]CXCL12 E15C and S16C, CXCR4(M24C) with and N44C, and CXCR4(K25C) with [P2G]CXCL12(A21C), which had low anti-HA detection by flow cytometry, showed low-to-negligible co-migrating chemokine in this experiment as well ( Fig 3A and 3B) . For the CRS0.5 interface, the pull-down/Western blotting results reiterated the anti-parallel geometry of the CXCR4 N-terminus and [P2G]CXCL12 β1-strand ( Fig 3A and 3B) . In particular, the detection of the S9C-L29C complex, consistent with the alternative, parallel β-sheet geometry at this site ( Fig 2B) , was negligible ( Fig 3A   and 3B ), suggesting that such geometry is unlikely or unstable. In general, crosslinked chemokine quantification by pull-down and Western blotting agreed well with that by flow cytometry, indicated by their positive relationship (S4A Fig) . This confirmed that flow cytometry, while being much less labor-intensive, is sufficiently sensitive and predictive of the quantity of crosslinked complex in pulled down samples. For future studies, flow cytometry detection alone should be sufficient to map intermolecular residue proximities and to inform efforts of deducing receptor-chemokine interaction geometry by molecular modeling (below).
In addition to the amount of co-migrating chemokine, Western blotting allowed evaluation of an orthogonal property of the crosslinked complexes, namely, fraction of extracted receptor that was crosslinked with the chemokine, by comparing the intensities of receptor double bands on the blot. Such quantitation is not possible with flow cytometry. The control pair of CXCR4(D187C) and vMIP-II(W5C) formed nearly 100% crosslinked complex, as shown previously [6] , while for other crosslinking pairs, distinct chemokine-bound and unbound receptor species were observed ( Fig 3A) . As expected, these double bands collapsed into a single band in the presence of a reducing agent (S5 Fig) , except for the control that appeared partially resistant to reduction. For the positive crosslinked samples, we found that ~50% of total receptor was crosslinked relative to Table) , while for weaker crosslinks, this fraction was lower. In general, fraction crosslinked was correlated with the amount of co-migrating chemokine (S4B Fig) .
Experiment-guided molecular modeling of the CXCR4 N-terminus interaction with CXCL12
Based on the resulting residue proximities, we generated atomic-resolution models of the CXCR4-CXCL12 complex (S1 Fig) . For this, the fully flexible N-terminus of CXCR4 was subjected to biased probability Monte Carlo conformational sampling in internal coordinates [48] , starting from random initial conformations and in the context of a flexible-side-chain model of CXCL12. Three sulfated tyrosines (Y7, Y12 and Y21) were included in the receptor N-terminus, to better understand their role in chemokine recognition [19, 24, 49] . In the course of sampling, weighted harmonic distance restraints were imposed between all receptor-chemokine residue pairs that demonstrated >65% crosslinking efficiency in flow cytometry, including the seemingly contradictory pairs, with weights calculated by a linear transformation of the crosslinking efficiencies (S6 Fig,   S4 Table) . Crosslinking efficiencies determined by pull-downs and Western blotting were not used in modeling, to ensure that our crosslinking restraint set is large, unbiased, and methodologically uniform. Table) . To confirm mutual consistency between our approach and the resulting model, we introduced two explicit disulfides between residues pairs with high crosslinking efficiency by flow cytometry (K25C-E15C and G3C-L29C), and demonstrated that they can be accommodated with minor adjustments to the top-ranking geometry (S9 Fig) .
Detailed geometry of the complex between full-length CXCR4 and CXCL12
The best-scoring conformation of the complex featured the CXCL12 backbone geometry from PDB 3GV3 [50] (conformational cluster 2, S8 Fig and S3 Table) . It was thus merged with the previously published partial (CRS2) CXCR4-CXCL12 model [43] to produce a full-length complex. The merged complex was subjected to local gradient minimization with restraints, which improved the inter-helical packing in the TM domain as well as the packing of the chemokine globular core against it. Finally, the proximal N-terminus of CXCL12 was refolded in the newly shaped TM binding pocket (CRS2) to complete the model ( Fig 4A, S1 Data) .
The resulting full-length model featured multiple newly predicted, energetically favorable polar residue interactions; for example, charge-charge interactions of CXCR4 CRS1 residues E26 with CXCL12 R47 (β3strand), K25 with E15 (N-loop), D20 with K56 (C-terminal helix), and E15 with K43 (40s loop) ( Fig 4B, 4C and 4E). These interactions also persisted in at least two out of three top-ranking conformations of the partial complex (S7 Fig) . Furthermore, the model explained the important role of sulfated tyrosines in chemokine recognition: extensive interactions were observed between the sulfated Y21 and CXCL12 N22 (3 10 helix), N44, and N45 (40s loop) ( Fig 4C and 4F ). While these proximities were somewhat supported by pull-down and Western blotting ( Fig 3A and 3B ), they were not evident from flow cytometry ( Fig 2C) , and, consequently, were not included as distance restraints in modeling (S4 Table) . Thus, the identification of these interactions is not a trivial consequence of modeling restraints, but rather an unbiased reflection of true binding preferences.
These interactions are the key distinction between the lowest energy conformation and the other conformations (S7 Fig). Additionally, complementary charge-charge interaction clusters were predicted for the other sulfotyrosines in the receptor N-terminus (Y7 and Y12), the former with K24 and H25 in the chemokine β1and β2-strand, and the latter with K64 in its C-terminal helix ( Fig 4B and 4F ). All these interactions support the hypothesis that CXCL12 binding to CXCR4 is driven by electrostatics (S2 Fig) , and explain the role of individual basic residues in the chemokine.
Our previous efforts to model CRS2 interactions of the CXCR4-CXCL12 complex resulted in positioning of the CXCL12 distal N-terminus in the minor subpocket, similar to the CXCR4-vMIP-II crystal structure that was used as a modeling template [6] , with no occupancy of the major subpocket. However, the improved interhelical packing of the full-length model presented here allowed it to favorably and reproducibly accommodate the proximal N-terminus of CXCL12 in a new geometry, where it occupies the major subpocket ( Fig 4D, 4G and S10 Fig) . This contrasts the geometry of complexes from CC [7] and CX 3 C [8, 9] families, where the proximal N-terminus of chemokines occupies the minor subpocket instead (S10 Fig). The new geometry and the resulting occupancy of the major subpocket of CXCR4 by the proximal N-terminus of CXCL12 may be a defining feature for CXC receptor-chemokine selectivity against other subfamilies (CC and CX 3 C) (S10 interaction is locked (Fig 4 and S12A Fig) . An alternative explanation for these crosslinks involves the CXCL12 dimer, where the CXCR4 N-terminus in a fully extended conformation may reach CRS1 of the CXCL12 dimer partner (S12B Fig) . M16C, Y21C, and S23C with [P2G]CXCL12 H25C and CXCR4 G19C with [P2G]CXCL12 K27C. We therefore sought to determine if these proximities were consistent with other complex geometries proposed in the literature so far [6, 25, 51, 52] . Previously published geometries were also incompatible with the offending crosslinks and in fact, they are incompatible with the majority of crosslinking data generated here, including strong crosslinks such as CXCR4 K25C with CXCL12 E15C, CXCR4 Y21C with CXCL12 H17C, and CXCR4 Y7C with CXCL12 H25C (S11 Fig) . Therefore, in comparison with prior models, the model generated here displayed marked improvement in recognizing the strongest experimental crosslinks at shorter distances (S13
Validation of prospective predictions from the model in a functional assay
Our final model predicted several salt-bridge type interactions in CRS1 outside of the set of distance restraints used in the simulation, that were not predicted by previously published models [25, 51] . These included the interactions between CXCR4 E26 and CXCL12 R47, along with CXCR4 D20 and CXCL12 K56 ( Fig 5, S1 Data). Previous one-sided mutagenesis studies have suggested a role for D20 and E26 in CXCL12 binding [53, 54] ; however, their functional role has not been verified. Moreover, their exact pairing with CXCL12 residues in the complex has never been explored. Here, to validate model predictions, reciprocal charge reversal (a.k.a. charge-swap, S1 Table) mutagenesis was performed. Using a BRET-based β-arrestin-2 recruitment assay in HEK293T cells, we found that WT CXCL12 displayed reduced potency and efficacy with the charge reversal CXCR4 mutant E26R (pEC 50 6.68 ± 0.07, Emax 87.9 ± 3.8%, n=3), relative to WT CXCR4 (pEC 50 7.40 ± 0.04, Emax normalized to 100%, Fig 5A and 5B , Table 1 ), and these defects were not a result of impairments in receptor surface expression (S14 Fig). On the chemokine side, the R47E mutation resulted in a partial agonist with strongly deteriorated potency and efficacy with WT CXCR4 (pEC 50 6.50 ± 0.10, Emax 88.23 ± 6.6%, n=3) ( Fig 5A and 5B , Table 1 ). However, when CXCR4(E26R) was stimulated by CXCL12(R47E), β-arrestin-2 recruitment efficacy was restored to WT levels, and potency was restored partially (pEC 50 6.88 ± 0.08, Emax 101.8 ± 4.6%, n=3) ( Fig 5B) , which confirms the predicted pairwise interaction of E26 and R47. This rescue of function by CXCL12(R47E) was specific to CXCR4(E26R) and was not observed with a proximal CXCR4 mutation, D20R, consistent with the lack of direct interaction between CXCR4 D20 and CXCL12 R47 in the model (Fig 5C and 5D ).
Similar to the CXCR4 E26R, CXCR4 D20R demonstrated potency and efficacy deficits when stimulated with WT CXCL12 (pEC 50 6.79 ± 0.08, Emax 78.54 ± 4.1%, n=4) ( Fig 5E and 5F, Table 1 ). However, on the chemokine side, the introduction of charge-reversal glutamic acid substitution on residue K56 did not lead to any detectable signaling deficits with WT CXCR4 (Fig 5E and 5F) . Consequently, functional rescue of CXCR4 D20R with CXCL12 K56E was not attempted. With the highly positive electrostatic surface of CXCL12 (S2 Fig) , it is conceivable that a single mutation does not result in a functional deficit. Overall, the pairwise chargeswap validation of the CXCR4 E26 and CXCL12 R47 interaction, as well as the loss of function with CXCR4 D20R mutation, provide strong prospective validation and support for our proposed CXCR4-CXCL12 geometry.
Discussion
Many GPCRs have extended flexible N-termini, which are often post-translationally modified and contribute to ligand binding and receptor signaling [55] . For chemokine receptors, the N-terminus is known to be a determinant of chemokine affinity and to contribute to specificity [14, 17] }; it is also increasingly being appreciated for its role in signaling efficacy [18, 22, 23] . However, because the distal N-termini of receptors are invariably unresolved in receptor-chemokine crystal structures, the structural basis for their regulation of chemokine affinity and signaling remains elusive.
Previous efforts to understand receptor-chemokine interactions have been predominantly "single-sided", i.e. directed at characterization of binding surfaces of individual partners rather than pairwise interaction geometry (S1 Table) . On the chemokine side, most of these studies established the N-loop/40s loop cleft as the key receptor binding interface [24, 26, 30, 31] , whereas some also pointed towards the involvement of CXC chemokine β1-strands. For example, in transferred cross-saturation NMR experiments, several CXCL12 β1strand residues (L26, I28 and L29) displayed enhanced signal reduction ratios in the presence of detergentsolubilized CXCR4 [56] . Similarly, in a radiolytic footprinting study, detergent-solubilized ACKR3 protected the same CXCL12 residues from radiolytic oxidation [34] . Perturbations of the CXCL8 β1-strand were also reported upon binding of soluble or membrane-bound CXCR1 N-terminus in solution NMR [26, 57] , and β1strand mutations weakened the affinity and potency of CXCL8 towards CXCR1/2 [58, 59] .
To deduce the geometry, and hence the structural basis for these phenomena, a series of complementary NMR studies were conducted; in these studies, isolated N-terminal peptides, rather than full-length receptors, were used. This approach bypasses challenges of purifying stable receptors in a membrane-like environment, and can often capture dominant intermolecular proximities; however, the resulting interaction geometries often conflict with each other [24, 25, 30, 49, 60] and are also hard to reconcile with the receptor TM domains [32, 33] .
Recently, two independent studies postulated direct binding of receptor distal N-termini to the β1-strand of CXCL12: an NMR study [25] utilized pairwise proximities from intermolecular NOEs, did not involve the receptor TM domain, and yielded a parallel β-sheet geometry, whereas our study [34] involving a full-length homologous receptor ACKR3 but only one-sided interaction evidence by radiolytic footprinting, proposed an anti-parallel β-sheet.
The present work resolves these ambiguities. Using disulfide crosslinking, we mapped, in a comprehensive and unbiased manner, pairwise residue proximities between the N-terminus of CXCR4 and [P2G]CXCL12, hence collecting unique interaction geometry information unattainable by the traditional "single-sided" approaches. Importantly, our effort was undertaken using a full-length receptor, hence avoiding artefacts caused by the absence of the TM domain. As a result, we not only successfully recapitulated the CRS1 consistent with earlier NMR studies, models and crystal structures of homologous receptors, but also established the geometry of the novel CRS0.5, where the distal N-terminus of CXCR4 extends into an anti-parallel β-sheet with the β1-strand of CXCL12. The crosslinking-derived proximities were combined with molecular modeling to produce a complete atomic-resolution model of the complex between CXCL12 and full-length CXCR4, which was then validated prospectively both through loss-of-function and reciprocal charge reversal mutagenesis (the latter an orthogonal experimental technique for testing pairwise residue interactions (S1 Table and [22] )).
The model, and in particular the novel CRS0.5 interface, reveal unique structural principles of CXC receptorchemokine recognition, regulation, and signaling, as well as the basis of selectivity against other subfamilies.
For example, unlike in the CC chemokine case [61] , dimerization and receptor binding are not mutually exclusive for CXC chemokines [6] : the dimeric forms of such chemokines can activate receptors, albeit with affinity and pharmacology that are different from the monomers [24, [62] [63] [64] . Because the receptor-chemokine interaction in CRS0.5 mimics and competes with CXC chemokine dimerization, it provides a structural basis for these differences. Moreover, CRS0.5 also explains the previously observed intriguing effects of β1-strand mutations on CC vs CXC chemokine selectivity, where CC-mimicking mutations in the CXCL8 β1-strand endowed it with CC chemokine characteristics, including monocyte chemotactic activity and CCR1 binding [58, 59], whereas reciprocal mutations bestowed neutrophil chemotactic activity (intrinsic to CXC chemokines) onto CCL2 [65] . Finally, the selectivity insights from the model extend beyond CRS0.5: we also propose the basis for unique engagement of the proximal chemokine N-terminus in the major subpocket of the receptor, where the conserved arginine residue preceding the chemokine CXC motif (R8 in CXCL12) is coordinated by the conserved acid in the receptor TM6 position 6.58 (D262 6.58 in CXCR4, Fig 4G) . This engagement depends on a unique CXC-motif-dependent "bend" [6] in the chemokine N-terminus [6, 60] , and may be a distinguishing feature of CXC complexes (S10 Fig). In the case of CXCR4-CXCL12, it is consistent with the reports of deleterious effects of D262 6.58 and R8 mutations, respectively [22, 25, 33] . It is also consistent with earlier observations of the critical role of the "ELR motif" in other, neutrophil-activating CXC chemokines [66, 67] , as well as the corresponding TM6 residue of neutrophil chemotactic CXC receptors [68, 69] (D265 6.58 in CXCR1).
Both the chemokine N-terminal "bend" and the conserved CXC-specific recognition determinants are absent in the CC and CX 3 C complexes [7-9] (S10 Fig), and thus, contribute to inter-subfamily selectivity.
In fact, the CXCR4-CXCL12 complex may be unique compared to other CXC subfamily receptor-chemokine pairs. First, it extensively relies on the chemokine distal N-terminus interactions with the minor subpocket [10, 33] . This is in contrast to other, neutrophil-specific CXC complexes that tolerate N-terminal truncations up to the ELR motif in the chemokine with only minor impairment of signaling [66, 70] . Additionally, CXCR4 features a basic amino acid (R30) two residues downstream of the N-terminal cysteine, which is a characteristic of CC rather than CXC receptors [60] . We hypothesize that these features allow CXCR4 to bind, with high affinity, to the virally encoded CC chemokine vMIP-II [6] , which itself mimics CXC chemokines by having a unique arginine (R7) in the proximal N-terminus, highly important for receptor binding [71] (S10 Fig). Therefore, the features identified by the present CXCR4-CXCL12 model explain not only CXC vs CC/CX 3 C selectivity, but also the rare and seemingly paradoxical coupling between a CXC receptor and a CC chemokine.
Our results suggest the structural basis by which tyrosine sulfation of the CXCR4 N-terminus improves its binding affinity for CXCL12. Corroborating our predictions, earlier NMR studies of CXCL12 with sulfotyrosinated receptor N-terminal peptides identified sY21 to be positioned similarly in the CXCL12 Nloop/40s-loop groove and interacting with N22 and N46 (compared to the cluster of N22, N44 and N45 in our model, Fig 4C) [24, 49] . The predicted interactions of sY21 with an asparagine cluster of CXCL12 are reminiscent of CCR5 sulfotyrosine recognition by a similar cluster of the HIV envelope glycoprotein gp120 [72] , suggesting that asparagine clusters may constitute preferred sulfotyrosine binding motifs. By contrast with sY21, the placement of other sulfotyrosines in earlier NMR-derived CXCR4-CXCL12 models is incompatible with the spatial constraints imposed by the receptor TM domain and the structurally determined receptorchemokine architecture [6, 33] . This reiterates the importance of studying receptor-chemokine interactions in the context of the full-length receptor.
Interestingly, ambiguities in the crosslinking data allowed for several alternative CXCR4-CXCL12 complex geometries, among which we identified the most probable and favorable one by flexible molecular docking in the presence of weighted local distance restraints. The locality ensured that the maximum number of restraints was satisfied in the final model, hence overcoming the ambiguous signal across the proposed interaction sites.
This approach is conceptually similar to NOE-based distance restraints in NMR structure calculations [30] .
Importantly, alternative geometries captured in the sampling procedure may represent biologically relevant intermediates (S12 Fig). A limitation in our modeling approach is that the orientation of the chemokine globular core with respect to the receptor TM domain, and activation state of the latter, originated from the CXCR4-vMIP-II antagonist crystal structure and were only locally minimized in the course of full model assembly, whereas more recent structures demonstrate substantial variability in both [7, 8] . In future studies, molecular dynamics will be required to thoroughly sample the system and identify more precisely the positioning of the CXCL12 globular core with the bound receptor N-terminus relative to the rest of the receptor.
To detect and quantify covalent receptor-chemokine complexes, we developed a medium-throughput flowcytometry-based screening approach. The method is performed in a multi-well format and does not require sample lysis, extraction or purification, nor does it depend on unnatural amino acids or photoaffinity labeling, hence contrasting and improving on previous crosslinking studies of GPCR-protein complexes [33-35, 73, 74] .
Nevertheless, there are caveats inherent to disulfide crosslinking, resulting in several crosslinks that could not be explained by any of the proposed CXCR4-CXCL12 complex geometries. First, cysteine mutations may lead to protein destabilization, misfolding (e.g. CXCL12 L26C and I28C mutations), or loss of binding.
Additionally, introducing additional cysteines in the already cysteine-rich environment of chemokines and receptors increases the possibility of intramolecular or intermolecular disulfide shuffling upon folding or complex formation [35] .
Despite these limitations, the comprehensive, systematic, and unbiased manner in which disulfide crosslinking was performed and interpreted here allowed us to distinguish native residue proximities with high confidence 
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Methods
Molecular Cloning
For crosslinking studies in Spodoptera frugiperda (Sf9) cells, cysteine mutations were introduced into the Nterminally Flag-tagged, C-terminally His-tagged CXCR4-T4 lysozyme fusion construct in pFastBac1 (CXCR4-T4L) [32, 33] using QuikChange mutagenesis (Agilent). Cysteine mutations were also generated for the antagonist CXCL12 variant [P2G]CXCL12, with its native signal sequence and a C-terminal HA tag (YPYDVPDYA), subcloned into pFastBac1 ([P2G]CXCL12-HA). The CXCR4(D187C)-T4L and vMIP-II(W5C) mutants and the C-terminally tagged ACKR3-Flag construct were previously described [6, 34] . For recombinant chemokine production, a pET21a-based construct of human CXCL12α (residues 22-89) lacking the endogenous signal peptide and preceded by an enterokinase recognition site and His8 tag [34, 75] was used as the WT construct; CXCL12 R47E and K56E mutations were introduced into this construct using QuikChange mutagenesis (Agilent). For pharmacological assays in HEK293T cells, the wild type CXCR4 fused with Renilla luciferase 3 (Rluc3) on the C-terminus and β-arrestin-2 fused N-terminally to GFP10 constructs in pcDNA3.1+ were generously provided by Nikolaus Heveker (Université de Montréal, Montreal, QC, Canada).
An HA tag following the CXCR4 start codon and D20R and E26R mutations were introduced by QuikChange mutagenesis (Agilent).
Expression and production of recombinant chemokines in E. coli
Chemokine expression and purification protocol was adapted from [34] . Chemokine-encoding plasmids were transformed into BL21(DE3)pLys competent cells. Cells were grown at 37°C with shaking at 180 rpm to an optical density of 0.6-0.7 in Luria-Bertani (LB) medium, and protein expression was induced by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). 
Production of receptor and chemokine viruses for co-expression in Sf9 cells
Spodoptera frugiperda (Sf9) insect cells were maintained in ESF 921 media (Expression Systems) in vented
Erlenmeyer flasks (Corning) at 27°C with shaking at 130 rpm.
Receptor and chemokine baculovirus stocks were produced using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Briefly, 2.5 mL of Sf9 cells at a density of 1.2×10 6 cells/mL were transfected with 5 µL of recombinant bacmid containing the gene of interest using 3 µL of X-tremeGENE HP DNA transfection reagent (Roche) and 100 µL of transfection medium (Expression Systems), and incubated for 96 h with 300 rpm shaking at 27°C. Following cell centrifugation at 2,000 g for 10 min, the P0 virus (supernatant) was isolated and 400 µL of P0 virus was immediately added to 40 mL of Sf9 cells at a density of 2-2.6×10 6 cells/mL for generation of P1 virus. Cells were incubated for 48 h with 130 rpm shaking at 27°C and centrifuged at 2,000 g for 10 min; the supernatant containing the P1 virus was harvested and stored at 4°C until further use. Viral titers were calculated in infectious units (IU)/mL as previously described [76] . Briefly, 20 µL of serial P1 virus dilutions (1 in 250, 500, 1000 and 2000) was added to 100 µL of Sf9 cells at a density of 1.2×10 6 cells/mL in a 96-deep well block and incubated for 18 h with 300 rpm at 27°C. The percentage of cells infected by virus was quantified by flow cytometry following staining of 10 µL of cells with 10 µL of PE-conjugated anti-gp64 antibody (Expression Systems, catalog #97-201) for 20 min in the dark at 4°C. The anti-gp64-PE antibody was pre-diluted 1:100 in Tris-buffered saline (TBS; 50 mM Tris pH 7.5, 150 mM NaCl) and 4% BSA. Following incubation, samples were made up to 200 µL with TBS+4% BSA and analyzed using a Guava benchtop miniflow cytometer (EMD Millipore). Virus titer was quantified as an average of (total cell number×%gp64 staining×virus dilution factor)/20 µL (volume of inoculum).
Detection of covalent receptor-chemokine complexes by flow cytometry
Flow cytometry used to initially detect disulfide cross-linked complexes on the cell surface was adapted from [35] . Briefly, 2.5 mL of Sf9 cells at a density of 2-2.6×10 6 cells/mL in a 24-deep well block were co-infected with receptor and chemokine P1 virus, each at a multiplicity of infection (MOI; IU/cell) of 8. Cells were incubated with 300 rpm shaking at 27°C. After 48 h, 10 µL of cell samples were transferred into a 96 well assay plate and incubated for 20 min in the dark at 4°C with 2 µL 7-amino-actinomycin D viability staining solution (eBioscience, catalog #00-6993-50) and 10 µL anti-HA FITC-conjugated antibody (Sigma-Aldrich, catalog #H7411), the latter pre-diluted 1:100 in TBS+4% BSA. Following incubation, samples were made up to 200 µL with TBS+4% BSA and analyzed using a Guava benchtop mini-flow cytometer (EMD Millipore). In all experiments, the previously characterized CXCR4(D187C)-vMIP-II(W5C) crosslinked pair [6] was used as a positive control. For data analysis, the geometric mean fluorescence intensity (GMFI) value of the live cell population was used. Crosslinking efficiency by flow cytometry was determined as GMFI for the receptorchemokine pair in relation to CXCR4(D187C)-vMIP-II(W5C), which was set to 100%. All flow cytometry data analysis was performed using FlowJo software v10.3 (FlowJo LLC).
Metal affinity pull-down of covalent receptor-chemokine complexes from Sf9 cells
To confirm the receptor-chemokine crosslinks detected by flow cytometry, metal affinity pull-downs were performed using the His-tag on the receptor, with subsequent receptor and chemokine detection by SDS-PAGE and quantification by Western blotting. Forty mL of Sf9 cells at a density of 2-2.6×10 6 cells/mL were infected with receptor and chemokine virus, each at an MOI of 5, and incubated for 48 h with 130 rpm shaking at 27°C.
Biomass was harvested by centrifugation (2,000 g for 15 min) and stored at -80°C until further use.
Cell pellets were thawed and resuspended in hypotonic buffer [10 mM HEPES, pH 7.5, 20 mM KCl, 10 mM MgCl 2 , 1× cOmplete EDTA-free protease inhibitor (Roche)]. Purified membranes were prepared by three rounds of dounce homogenization (approximately 40 strokes per round) and centrifugation of the cell suspension at 50,000 g for 30 min at 4°C. Following the first round of homogenization, membrane pellets were resuspended in a high salt buffer (10 mM HEPES pH 7.5, 10 mM MgCl 2 , 20 mM KCl, 1 M NaCl and 1× cOmplete EDTA-free protease inhibitor) which was also used during the subsequent rounds. After the last round of centrifugation, membranes were resuspended and homogenized in hypotonic buffer supplemented with 30% glycerol (v/v) and flash-frozen for storage at -80˚C until further use.
The purified membranes were thawed and iodoacetamide (2 mg/mL) added. Membranes were mixed with an equal volume of 2× solubilization buffer [100 mM HEPES pH 7.5, 800 mM NaCl, 1.5% n-dodecyl-ß-Dmaltopyranoside (DDM, Anatrace), 0.3% cholesteryl hemisuccinate (CHS, Sigma)] for 4 h at 4°C, and centrifuged at 25,000 g for 30 min. The supernatant was incubated with TALON IMAC resin (Clontech) and 25 mM of imidazole overnight. The samples were centrifuged at 350 g for 5 min, and the resin was transferred to gravity flow columns. The resin was washed with 20 column volumes of Wash Buffer 1 (25 mM HEPES, pH 7.5, 400 mM NaCl, 10% glycerol, 0.1/0.02% DDM/CHS, 10 mM imidazole) followed by 10 column volumes of Wash Buffer 2 (25 mM HEPES, pH 7.5, 400 mM NaCl, 10% glycerol, 0.025/0.005% DDM/CHS, 10 mM imidazole). Complexes were eluted with 3 column volumes of elution buffer (Wash Buffer 2 with 250 mM imidazole) and the eluted protein was exchanged into Wash Buffer 2 without imidazole using 0.5 mL 100 kDa molecular weight cutoff spin concentrators.
Characterization of covalent receptor-chemokine complex formation by SDS-PAGE and Western blotting
Protein samples from metal affinity pull-down experiments were analyzed for formation of crosslinked complexes by SDS-PAGE followed by Coomassie staining or Western blotting [35] . Samples (1 µg total protein) were loaded onto non-reducing 12% Mini-PROTEAN ® TGX™ precast gels (Bio-Rad), and molecular weight shifts and relative band intensity used to detect the presence and relative abundance of the crosslinked complex. For Western blotting, gels were transferred onto nitrocellulose membranes (Bio-Rad, catalog #1704270) using the Trans-Blot ® Turbo™ transfer system, and blocked with 5% skim milk overnight at 4°C.
The Flag-tagged receptor was detected using mouse anti-Flag M2 primary antibody (1:10,000 dilution; Sigma Aldrich, catalog #F3165) and IRDye ® 680RD-conjugated donkey anti-mouse IgG secondary antibody (1:20,000 dilution; LI-COR Biosciences, catalog #926-68072). HA-tagged [P2G]CXCL12 was detected using a rabbit anti-HA primary antibody (1:10,000 dilution; Sigma Aldrich, catalog #SAB4300603) and IRDye ® 800CWconjugated goat anti-rabbit IgG (1:20,000 dilution; LI-COR Biosciences, catalog #926-32211) secondary antibody. Primary antibodies were incubated simultaneously for 1 h at room temperature, followed by the secondary antibodies for a further 1 h at room temperature. Primary and secondary antibodies were diluted in TBS with 0.5% Tween-20 and 5% skim milk or 1% BSA, respectively. Membranes were imaged using the Odyssey IR imaging system (LI-COR Bioscience). For reducing conditions, samples were incubated with 100 mM DTT for 30 min at room temperature prior to loading onto gels.
To quantify the amount of crosslinked chemokine, a rectangle was drawn on the anti-HA Western blot that captures the crosslinked chemokine band, and IR800 signal intensity within the rectangle was recorded as reported by ImageStudioLite (LI-COR Biosciences). This value was normalized to CXCR4(D187C)-vMIP-II(W5C), where its IR800 signal was set to 100%, and used as the crosslinking efficiency by Western blot. To calculate the percentage of crosslinked receptor, the same chemokine rectangle was used to capture the upper chemokine-crosslinked receptor band, and a second rectangle was drawn to capture total receptor. The percent crosslinked receptor was determined by: upper band IR680 signal/total receptor IR680, where IR680 reports the receptor Flag tag. The area of the rectangles was kept consistent for all samples within a single Western blot.
Molecular modeling
All molecular modeling was carried out using ICM [48] v3.8-6 or higher (Molsoft LLC) and the previously published incomplete model (residues P27-F304) in complex with CXCL12 [6] . The N-terminal peptide M1-P27 was constructed ab initio, tyrosines Y7, Y12, and Y21 were sulfated [19, 24] , and residue P27 was tethered to its position in the earlier model. Weighted local harmonic distance restraints were imposed between Cβ atoms (or Cα atoms for Gly) of those CXCR4 and CXCL12 residues that displayed >65% crosslinking efficiency by flow cytometry. The conversion of crosslinking efficiencies into weights involved a linear normalizing transformation so that the weights ranged from 0.5 to 5 (S4 Table) . The mechanism of local distance restraints favors proximal restrained atom pairs, with restraint energy gradually becoming weaker (less favorable) and approaches an asymptote as the distance between the two atoms grows, rather than increasing indefinitely (S15 calculated using the Lennard-Jones potential and capped at 7 kcal/mol (the so-called "soft" van der Waals energy), hydrogen bonding term, electrostatics, torsional strain, tethers and a medium-strength penalty (cnWeight = 5) for distance restraints (ICM energy/penalty term "cn", short for "contacts"). To account for backbone flexibility of CXCL12, parallel simulations were run with alternative backbone conformations; for this, crystal structures of CXCL12 were clustered by the geometry of the 30s and 40s loop, and the highest resolution structure was selected as the representative conformation for each cluster (Fig 1C, S1 Table) . Each system was sampled by biased probability Monte Carlo [48] (BPMC) for 3×10 7 steps, and the lowest energy conformations were stored.
The top-ranking conformation of the CXCR4 N-terminus with CXCL12 was merged with the rest of the receptor [6] to build a complete model of the complex. The globular core of the chemokine was superimposed onto that of the partial model, after which contiguous CXCR4 and CXCL12 polypeptide chains were generated ab initio and threaded through the respective parts of the overlay, recapitulating the CRS0.5 and CRS1 interactions determined above, as well as previously published CRS2 interactions [6] . The model was then subjected to global refinement with restraints. For this, 264 harmonic global distance restraints were imposed in place of the inter-and intramolecular hydrogen bonds: the intramolecular bonds were extracted from the separate crystal structures of the two proteins (CXCR4: PDB 3ODU [32] and 4RWS [6] ; CXCL12: PDB 3GV3 [50] ), while the intermolecular hydrogen bonds were inferred from the CRS interfaces from the model in the prior step. Three additional hydrogen-bond-compatible global distance restraints were added: one between CXCR4 E277 and CXCL12 R12 that were previously predicted and recently experimentally proved to directly interact [22] , another between CXCR4 Q200 and D262, to promote closure of the gap between TM helices 5 and 6 that is observed in CXCR4 crystal structures, and the third between CXCR4 D181 and CXCL12 K27, which were proximal in the original model but outside of the hydrogen bonding distance. The last restraint promoted slight re-orientation, and better packing, of the globular core of CXCL12, together with the bound CXCL12 N-terminus, with respect to CXCR4 TM domain. Next, the system was subjected to a refinement protocol consisting of global BPMC sampling of receptor and chemokine residue side-chains, with each sampling step followed by 500 steps of local gradient minimization of the entire system (backbone and sidechains) in internal coordinates. The objective (energy) function included full atom soft van der Waals term capped at 20 kcal/mol, hydrogen bonding term, electrostatics, torsional strain, surface energy, and the penalty for the distance restraints. After 10 6 minimization steps, two loops, one involving CXCL12 residues 3-7, and another CXCR4 residues 224-236 (ICL3), were refolded using the ICM loop modeling toolkit. Briefly, this involved finding, by BPMC, the optimal conformation for each loop in the context of the rest of the model, with the loop represented as an isolated peptide with termini tethered to their positions in the model, and the rest of the model represented as energy potentials (van der Waals, electrostatics, hydrogen bonding, and surface energy) precalculated on a 0.5Å 3D grid [77] . The best conformations were merged into the full-model of the complex, and the model subjected to additional 2×10 6 steps of the above refinement protocol, to ensure that the energy close to the local minimum is achieved.
BRET2 β-arrestin recruitment assay
β arrestin-2 recruitment was measured with a bioluminescence resonance energy transfer 2 (BRET2) assay [78] as described previously [34] . Briefly, HEK293T cells were seeded in tissue-culture-treated 6-well plates at 7×10 5 cells cells per well in Dulbecco's Modified Eagle Media (DMEM) + 10% fetal bovine serum (FBS). Next day, cells were co-transfected with 50 ng/well WT or mutant HA-CXCR4-Rluc3 and 2400 ng/well GFP10-β-arrestin-2 using TransIT-X2 transfection reagent (MirusBio), according to the manufacturer's recommended protocol. Two days after transfection, cells were washed with PBS, re-suspended in PBS + 0.1% D-glucose (BRET buffer), and diluted to 1-1.5×10 6 cells/mL. Cells were aliquoted at 1.5×10 5 cells per well into a white, clear bottom, tissue culture treated 96-well plate (Corning) and the plate was incubated for 30 min at 37°C, after which GFP10-β arrestin-2 fluorescence levels were measured with the TriStar LB 941 plate reader (Berthold Biotechnologies). Next, recombinant WT or mutant CXCL12 was added to each well at indicated final concentrations and incubated for 10 min, after which coelenterazine-400A (a.k.a. DeepBlueC) was added to a final concentration of 5 uM immediately before measuring the emission at both 410 and 515 nm using the TriStar LB 941 plate reader. BRET ratios (emission at 515 nm/emission at 410 nm) were calculated, and threeparameter agonist concentration response curve fitting was carried out using GraphPad Prism (GraphPad Software Inc). BRET2 values were baseline-corrected and normalized to CXCR4(WT)-CXCL12(WT) levels within each experiment. The extra sum-of-squares F test was used to compare curve fit parameters and determine statistically significant differences between WT and mutant receptors and chemokines. Results are listed in text as pEC 50 /Emax +/-the standard error for that parameter, when normalized values from at least three independent experiments were fit together.
Detection of CXCR4 surface expression by flow cytometry
The cell surface expression of WT HA-CXCR4-Rluc3 and mutants was monitored by flow cytometry using the same cells as in the BRET experiments above. Cells resuspended in BRET buffer were aliquoted at 1. Table. (B) The exposed structural elements of CXCL12 highlighted on the crystallographic ensemble of structures. (C) Coordinated conformations of CXCL12 structural elements, that are indicated by asterisks in (A), captured by clustering of the 30s loop. (D-E) Normalized residue side chain SASA (D) and side chain conformational variability (E) mapped onto the CXCL12 surface. The highly flexible N-and C-termini are colored orange. (F) Exposed residue backbones, polar and nonpolar side chains on the CXCL12 surface. In (D-F), the black strokes highlight surface grooves in CXCL12. (G-H) A coarse-grain hypothesis of CXCR4 (grey) bound to CXCL12 (surface mesh is colored by known and proposed chemokine recognition sites (CRS) between the receptor and chemokine). The hypothesis is based on published CRS2 models and the presented structural and physicochemical properties of CXCL12.
Fig 2. CXCR4-[P2G]CXCL12 intermolecular crosslinking efficiencies detected by flow cytometry. (A)
A heat map of pairwise crosslinking efficiencies in the predicted CRS0.5, normalized to CXCR4(D187C)-vMIP-II(W5C), a previously crystallized covalent complex. (B) CRS0.5 crosslinking efficiencies mapped onto a 2D schematic of CRS0.5 in the hypothetical anti-parallel and parallel β-sheet orientations. The data is more consistent with the anti-parallel geometry. (C) A heat map of pairwise crosslinking efficiencies in CRS1, normalized to CXCR4(D187C)-vMIP-II(W5C). (D) CRS1 crosslinking efficiencies mapped onto a 2D schematic of CRS1. (E-F) Heat maps of pairwise crosslinking efficiencies when (E) Cys mutants in CXCR4 CRS1 are co-expressed with Cys mutants in CXCL12 β1-strand (CRS0.5) and (F) vice versa. Grey squares in the heat map represent residue pairs that were not studied. Data represents the average of n ≥ 3 independent biological replicates. The raw data is provided in S4 Table. , which drive CXCL12 binding to the receptor. The receptor is shown in black ribbon and the chemokine in molecular surface mesh. Polar, negatively-and positively-charged side chains on the surface are colored in cyan, red and blue respectively, while nonpolar surface is white. The chemokine residue labels are colored by their charge: negative (red) and positive (blue). In (E), dominant polar interactions in CRS0.5 and CRS1 with hydrogen bonds shown as orange dotted lines. (F) The predicted interactions between receptor sulfotyrosines and CXCL12 polar and charged residue clusters. (G) Predicted interactions of the CXCL12 N-terminus in the TM binding pocket of CXCR4. The binding of the proximal N-terminus of the chemokine in the major subpocket of the receptor is likely a defining feature for CXC receptor-chemokine complexes. The receptor is shown as a cutaway surface.
Fig 5. Validation of predicted interactions in CRS1 via reciprocal charge reversal substitutions in a BRET2-based β-arrestin recruitment assay. (A)
The predicted interaction between CXCR4 E26 and CXCL12 R47. (B) Individual charge reversals (E26R in CXCR4 or R47E in CXCL12) lead to substantial deficits in both potency and efficacy of β-arrestin recruitment; however, when these mutants are combined, the deficits are partially rescued. (C) According to the model, CXCR4 D20 and CXCL12 R47 are located 15.8Å away from each other, and do not interact. (D) Combining CXCR4(D20R) and CXCL12(R47E) does not rescue signaling deficits caused by each of these mutations individually. (E) The predicted interaction between CXCR4 D20 and CXCL12 K56. (F) Unlike CXCR4(D20R), the K56E mutation in CXCL12 does not cause any detectable signaling defects, therefore, functional rescue was not attempted. Data represents at least n=3 independent biological replicates. The mean and s.e.m is reported for each point. WT curves were obtained in parallel with each respective mutant. 
